DRUG FOR DIALYSIS-RELATED AMYLOIDOSIS

DRUG FOR DIALYSIS-RELATED AMYLOIDOSIS

UCLA Technology Available For Licensing

BACKGROUND: Amyloid formation plays a role in over 20 human diseases including Alzheimer's disease, type II diabetes and the systemic amyloidoses. Dialysis-related amyloidosis (DRA) occurs in dialysis patients when -2 microglobulin builds up in the blood and deposits in the joints as amyloid. DRA eventually affects all long-term kidney dialysis patients and is only effectively treated by kidney transplant; if left untreated, the systemic amyloidosis can be deadly. Over 300,000 people in the United States and over 1 million worldwide are on kidney or peritoneal dialysis. Finding a treatment to dissolve the -2 microglobulin fibrils would provide the only alternative to a kidney transplant for these patients.

INNOVATION: Researchers at UCLA have identified 2 compounds that disrupt preformed human -2 microglobulin fibrils in a dose-dependent manner at concentrations that are clinically relevant. Both of these compounds have been proven safe in clinical trials for other diseases and could be readily administered during dialysis. These compounds were identified using a high throughput screen developed by the researchers for the identification of drugs that dissolve fibrils. The developed assay can be used to find drugs that dissolve fibrils associated with other human diseases.

POTENTIAL APPLICATIONS

Treatment of dialysis-related amyloidosis
It is anticipated the drug could be added to the dialysis solutions given to dialysis patients to treat or prevent DRA
The assay may be used to identify drugs that dissolve fibrils associated with other human diseases

ADVANTAGES

Compounds already have a proven safety profile
Treatment for DRA would occur during normal dialysis treatment directly into patient blood where fibrils are found

Reference: UCLA Case No. 2006-584 PCT Application: WO/2008/076351

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property

11000 Kinross Avenue, Suite #200

Los Angeles, CA 90095-7231

Tel: 310-794-0558 Fax: 310-794-0638

email: ncd@research.ucla.edu

NCD URL: http://www.research.ucla.edu/tech/ucla06-584.htm

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/oipa/industry

keywords: therapeutic uclancd ucla technologies intellectual property patents technology transfer invention business card